The CRISPR-Cas gene-editing system has long been the focus of research as a promising tool in genome editing. However, the ...

The company's strong cash position gives investors confidence in the gene-editing stock.

A compact Cas12f nuclease shows high editing efficiency in human cells, with structural insights enabling an engineered variant potentially suited for future AAV‑compatible delivery.

Recent commentary has highlighted CRISPR Therapeutics’ expanding gene-editing pipeline, including cardiovascular candidates like CTX310 and CTX320 and programs in type 1 diabetes, alongside fresh Buy ...

Scientists have taken an important step toward a gene therapy that could one day turn off the extra genetic material that ...

CRISPR Cas9 gene therapy explained with DNA scissors, hereditary diseases treatment, and designer babies ethical dilemmas ...

A research team has discovered an enhanced CRISPR gene-editing system that could enable targeted delivery inside the human ...

The last time The Lancet Microbe featured an Editorial on CRISPR was in November 2020, to mark that year’s Nobel Prize in Chemistry, jointly awarded to Emmanuelle Charpentier and Jennifer A Doudna for ...

Scientists have gained tremendous control over the genome with CRISPR editing systems, that use a guide RNA molecule to ...

Key market opportunities include advancements in research, medicine, diagnostics, and biotechnology through CRISPR. There is potential for innovative solutions and ethical exploration in gene editing, ...

Revvity's Dharmacon All-in-one lentiviral platform has expanded to include whole-genome library options for CRISPR knockout (CRISPRko), CRISPR interference (CRISPRi), and CRISPR activation (CRISPRa).